Correlation between long-term outcome and steroid therapy in type 1 autoimmune pancreatitis: relapse, malignancy and side effect of steroid

References

• Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009;58:1504–7.
   PubMed Web of Science ®Google Scholar
• Matsushita M, Ikeura T, Fukui T, Uchida K, Okazaki K. Refractory autoimmune pancreatitis: azathioprine or steroid pulse therapy? Am J Gastroenterol 2008;103:1834; author reply -5.
   Web of Science ®Google Scholar
• Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013;62:1607–15.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Takahashi H, Tabeya T, Suzuki C, Naishiro Y, Ishigami K, et al. Risk of malignancies in IgG4-related disease. Mod Rheumatol 2012;22:414–18.
   PubMed Web of Science ®Google Scholar
• Shiokawa M, Kodama Y, Yoshimura K, Kawanami C, Mimura J, Yamashita Y, et al. Risk of cancer in patients with autoimmune pancreatitis. Am J Gastroenterol 2013;108:610–17.
   PubMed Web of Science ®Google Scholar
• Hirano K, Tada M, Sasahira N, Isayama H, Mizuno S, Takagi K, et al. Incidence of malignancies in patients with IgG4-related disease. Intern Med 2014;53:171–6.
   PubMed Web of Science ®Google Scholar
• Ostenfeld EB, Erichsen R, Thorlacius-Ussing O, Riis AH, Sorensen HT. Use of systemic glucocorticoids and the risk of colorectal cancer. Aliment Pharmacol Ther 2013;37:146–52.
   PubMed Web of Science ®Google Scholar
• Severi G, Baglietto L, Muller DC, English DR, Jenkins MA, Abramson MJ, et al. Asthma, asthma medications, and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2010;19:2318–24.
   Google Scholar
• Jensen AO, Thomsen HF, Engebjerg MC, Olesen AB, Friis S, Karagas MR, et al. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin’s lymphoma: a population-based case-control study. Br J Cancer 2009;100:200–5.
   Google Scholar
• Dietrich K, Schned A, Fortuny J, Heaney J, Marsit C, Kelsey KT, et al. Glucocorticoid therapy and risk of bladder cancer. Br J Cancer 2009;101:1316–20.
   PubMed Web of Science ®Google Scholar
• Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. Jama 2006;296:2823–31.
   PubMed Web of Science ®Google Scholar
• Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003;89:1221–7.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777–87.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 2014;32:337–50.
   PubMed Web of Science ®Google Scholar
• Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine 2012;41:183–90.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:628–34.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton IL, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19:893–9.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Chen L, Spettell C, McMahan RM, Fernandes J, et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum 2011;63:346–51.
   PubMed Web of Science ®Google Scholar
• Shimosegawa T; Working Group Members of the Japan Pancreas S, Research Committee for Intractable Pancreatic Disease by the Ministry of Labor H, Welfare of J. The amendment of the Clinical Diagnostic Criteria in Japan (JPS2011) in response to the proposal of the International Consensus of Diagnostic Criteria (ICDC) for autoimmune pancreatitis. Pancreas 2012;41:1341–2.
   Google Scholar
• Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011;40:352–8.
   PubMed Web of Science ®Google Scholar
• Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T, et al. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2012;42:139–47.
   PubMed Web of Science ®Google Scholar
• Kubota K, Watanabe S, Uchiyama T, Kato S, Sekino Y, Suzuki K, et al. Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids. J Gastroenterol 2011;46:834–42.
   PubMed Web of Science ®Google Scholar
• Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czako L, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013;62:1771–6.
   PubMed Web of Science ®Google Scholar
• Kim JH, Chang JH, Nam SM, Lee MJ, Maeng IH, Park JY, et al. Newly developed autoimmune cholangitis without relapse of autoimmune pancreatitis after discontinuing prednisolone. World J Gastroenterol 2012;18:5990–3.
   Google Scholar
• Moon SH, Kim MH, Park do H. Treatment and relapse of autoimmune pancreatitis. Gut Liver 2008;2:1–7.
   PubMed Web of Science ®Google Scholar
• Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology 2010;139:140–8; quiz e12-3.
   PubMed Web of Science ®Google Scholar
• Pezzilli R, Vecchiarelli S, Di Marco MC, Serra C, Santini D, Calculli L, et al. Pancreatic ductal adenocarcinoma associated with autoimmune pancreatitis. Case Rep Gastroenterol 2011;5:378–85.
   Google Scholar
• Motosugi U, Ichikawa T, Yamaguchi H, Nakazawa T, Katoh R, Itakura J, et al. Small invasive ductal adenocarcinoma of the pancreas associated with lymphoplasmacytic sclerosing pancreatitis. Pathol Int 2009;59:744–7.
   Google Scholar
• Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol 2006;18:129–34.
   PubMed Web of Science ®Google Scholar
• Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT. Risk of acute pancreatitis in users of azathioprine: a population-based case-control study. Am J Gastroenterol 2003;98:1305–8.
   PubMed Web of Science ®Google Scholar